The briefing
Reuters reports that South Africa’s Aspen Pharmacare will sell European commercialization rights and related IP for its women’s health product Ovestin to Ennogen Healthcare for €197 million ($220 million). The move is part of the company’s portfolio strategy in Europe.
Original headline
South Africa's Aspen Pharmacare to sell women's health product in Europe to Ennogen